Evidence map›Paper›PMID 39881874›Full record

ReviewFrontiers in pharmacology2024

A review of the

Ke Xu, Bowen Deng, Tongtong Jia, Mihong Ren, Hai Chen, Jing Zhang, Jinlin Guo, Yong Li, Jian Wang

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ke Xu *College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Bowen Deng *College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Tongtong JiaCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Mihong RenCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Hai ChenCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jing ZhangCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jinlin GuoCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Yong LiCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jian WangCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: The historical origins of BC in the treatment of IS were investigated through the examination of ancient Chinese medical texts. Furthermore, the chemical components of BC were analyzed, and its mechanisms of action against IS were summarized using literature sourced from databases such as Web of Science, PubMed, and China National Knowledge Infrastructure. Information on Chinese medicine preparations and clinical reports was also integrated to provide an overview of modern applications and safety considerations. Results: BC mainly includes chemical components such as bile pigments, bile acids, cholesterol, proteins amino acids, and trace elements. Additionally, the efficacy of BC in treating cerebral ischemia/reperfusion injury (CI/RI) is certain, particularly due to the components of bile pigments, bile acids, and amino acids that can interfere with the enzymatic cascade reaction of CI/RI through multiple components, targets, and pathways. The active components of BC exert neuroprotective effects by reducing microcirculation disturbance, excitatory amino acid toxicity, and oxidative stress injury in the acute stage; inhibiting inflammatory injury, apoptosis, and blood-brain barrier (BBB) disruption in the subacute stage; and promoting angiogenesis and neurogenesis in the restoration stage. Furthermore, as a crude drug, BC appears in many Chinese patent medicine (CPM) preparations for the treatment of IS, and clinical and preclinical studies have proved its safety. Conclusion: The use of BC in the treatment of IS has a long history, proven efficacy, and widespread application. Future efforts should focus on elucidating its mechanisms of action and exploring its applications.

Indexed as

Bovis Calculuschemical compositionclinical applicationdrug safetyischemia strokepharmacokineticspharmacological effecttraditional application

Identifiers

PMID39881874
PMCPMC11775449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.